Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals is a biotech powerhouse that specialises in developing life-changing medicines for serious, often rare, genetic conditions.
Is Vertex Pharmaceuticals Incorporated a good stock for a UK beginner?
The honest version: There's no rating here and nothing for sale. In its favour: Dominant market position in cystic fibrosis. Worth weighing: Heavy reliance on a single area of medicine.
Is this normal for this company?
Each figure against the range this same company has produced recently. Neither end of a range is the good end.
Share price divided by the earnings actually reported over the four most recent quarters. The range is the same calculation at each of this company's last few results, so roughly the past year.
Profit as a share of sales, from the company's own quarterly statements. The range covers the 5 quarters we hold, and the figure shown is its most recent one.
How these ranges are built
Every number here is the company's own reported figure, not a comparison with other companies. The ranges come from this company's own results and its share price. Where it reports in a different currency from the one its shares trade in, the price-to-earnings range is left out rather than mixing the two.
What does Vertex Pharmaceuticals Incorporated do?
Vertex is best known for its dominant position in treating cystic fibrosis, a condition where it has effectively created a monopoly through its specialised drugs. Selling these high-value treatments to patients worldwide funds the business, with those profits reinvested into researching new therapies for other complex diseases. Keep an eye on how successfully they expand beyond their core cystic fibrosis business into new areas like gene editing and pain management.
On our factor screen it looks strongest on quality and momentum, and weakest on income.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 12% over the year
- ✓Very profitable - turns about 35% of sales into profit
- !High P/E of 31 - big growth is already priced in
- ✓Low debt - a sturdier balance sheet
- ✓Strong return on shareholder money (ROE 24%)
- Quality screens high
- Momentum screens high
- Value screens low
- Income screens low
Does Vertex Pharmaceuticals Incorporated pay a dividend?
No - Vertex Pharmaceuticals Incorporated doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
Does Vertex Pharmaceuticals Incorporated have more cash or more debt?
It holds about $7.85B in cash against about $1.98B of debt - so it has net cash of about $5.87B. More cash than debt is a cushion: it does not need to borrow just to cover what it owes.
From the latest reported balance sheet. Cash and debt levels change, and some borrowing is normal - this is context, not a judgment.
What do Vertex Pharmaceuticals Incorporated's numbers mean?
How has it performed?
Growth of £1,000, the worst fall, and year by year
Over about 2 years to 2026-09-11. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
How much has Vertex Pharmaceuticals Incorporated actually fallen?
Over the last 2 years of daily prices, Vertex Pharmaceuticals Incorporated fell as much as −29% from a high to a later low. Falls like this are normal when you own a share.
Past falls are not a forecast - it can fall further, or recover.
How has it done year by year?
Calendar-year total return - the share price with dividends reinvested - from adjusted closing prices. The current year is only part-complete. Past returns are not a guide to the future.
A closer look at the numbers
Ownership, earnings history, where the money goes, and the outlook range
Does the share price tell you if it's cheap or expensive?
Who owns Vertex Pharmaceuticals Incorporated?
About 99% of Vertex Pharmaceuticals Incorporated, or about 99 in every 100 shares, is held by big institutions such as pension and index funds. The rest, roughly 1%, is held by the public and smaller investors.
What this does and doesn't tell you
This is a recent snapshot of the share register, and it moves. We don't read anything into who owns what - a high institutional share is common for any large listed company and is not a signal about it.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
How much money does Vertex Pharmaceuticals Incorporated make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Where does each £100 of Vertex Pharmaceuticals Incorporated's sales go?
A rough split of the latest full-year figures: of every £100 of sales, about £45 covers making the product or service, £20 goes on running costs, tax and interest, and about £35 is left as profit. Margins vary a lot by industry, and one-off items can distort a single year.
When does Vertex Pharmaceuticals Incorporated report earnings, and how did recent quarters go?
Vertex Pharmaceuticals Incorporated is next scheduled to report on about 2026-11-02 - dates can move, and we don't predict results; this just tells you when to look.
‘Beat’ and ‘missed’ are against what analysts expected, not whether the business is doing well.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-08-03 | $4.75 | $4.73 | In line |
| 2026-05-04 | $4.31 | $4.47 | Beat +4% |
| 2026-02-12 | $5.15 | $5.03 | Missed -2% |
| 2025-11-03 | $4.58 | $4.80 | Beat +5% |
| 2025-08-04 | $4.25 | $4.52 | Beat +6% |
| 2025-05-05 | $4.29 | $4.06 | Missed -5% |
Across the last 6 quarters here, Vertex Pharmaceuticals Incorporated came in ahead of what analysts expected 3 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Where these figures come from
Each quarter a company reports its results against a consensus of analyst forecasts. The figures here are reported versus expected earnings per share from published results; the expectation is that analyst consensus, not our view. Report dates are estimates and can move.
What are the scenarios for Vertex Pharmaceuticals Incorporated?
An illustrative range for the year ahead — not a prediction or a price target.
What are the pros, cons and common questions?
The case each way, and the questions people ask
Vertex becomes a multi-disease leader with several blockbuster drugs.
Failure to innovate beyond their current core products.
What are the pros and cons of Vertex Pharmaceuticals Incorporated?
A balance check, not a score or verdict.
- Dominant market position in cystic fibrosis
- Very high profit margins
- Strong track record of scientific innovation
- Low share price volatility compared to the market
- Heavy reliance on a single area of medicine
- No dividend payments for income-focused investors
- High price-to-sales ratio suggests a premium valuation
- High failure rate of new drug development
- Potential for government pressure on drug pricing
- Patent expirations could open the door to cheaper rivals
The write-up's own warning lights — if these start happening, the case above changes.
- A major, unexpected failure in a key clinical trial
- A significant change in how governments reimburse expensive drugs
Common questions about Vertex Pharmaceuticals Incorporated
Does Vertex Pharmaceuticals Incorporated pay a dividend?
No - Vertex Pharmaceuticals Incorporated does not currently pay a dividend, so the return would rest on the share price. Many growing companies reinvest profits instead of paying them out.
When does Vertex Pharmaceuticals Incorporated report earnings next?
Vertex Pharmaceuticals Incorporated is next scheduled to report results on about 2026-11-02. Report dates are estimates and can move; this is a diary note for when to look, not a forecast of the outcome.
More in Healthcare
McKesson Corporation
Pfizer Inc.
Zoetis Inc.
Becton, Dickinson and Company
UnitedHealth Group Incorporated
Edwards Lifesciences Corporation
Boston Scientific Corporation
Veeva Systems Inc.Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.